PerCP/Cy5.5® Anti-VEGF Receptor 2 antibody [Avas12a1] (ab253080)
![Flow Cytometry - PerCP/Cy5.5® Anti-VEGF Receptor 2 antibody [Avas12a1] (ab253080)](https://www.abcam.com/ps/products/253/ab253080/Images/ab253080-343653-ab253080343653antovegfreceptor2monoclonalantibodyavas12a1floecytometrymouse-j.jpg "Flow Cytometry - PerCP/Cy5.5® Anti-VEGF Receptor 2 antibody [Avas12a1] (ab253080)")
Key features and details
- PerCP/Cy5.5® Rat monoclonal [Avas12a1] to VEGF Receptor 2
- Suitable for: Flow Cyt
- Reacts with: Mouse
- Conjugation: PerCP/Cy5.5®. Ex: 482nm, Em: 690nm
- Isotype: IgG2a
Overview
-
Product name
PerCP/Cy5.5® Anti-VEGF Receptor 2 antibody [Avas12a1]
See all VEGF Receptor 2 primary antibodies -
Description
PerCP/Cy5.5® Rat monoclonal [Avas12a1] to VEGF Receptor 2 -
Host species
Rat -
Conjugation
PerCP/Cy5.5®. Ex: 482nm, Em: 690nm -
Tested applications
Suitable for: Flow Cytmore details -
Species reactivity
Reacts with: Mouse -
Immunogen
The details of the immunogen for this antibody are not available.
-
Positive control
- Flow cyt: bEnd-3 cells.
-
General notes
This product or portions thereof is manufactured under license from Carnegie Mellon University under U.S. Patent Number 5, 268, 486 and related patents. Cy and CyDye are trademarks of GE Healthcare Limited.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. Store In the Dark. -
Storage buffer
pH: 7.20
Preservative: 0.09% Sodium azide
Constituents: 0.16% Sodium phosphate, 0.87% Sodium chloride, 0.1% Gelatin -
Concentration information loading... -
Purity
Affinity purified -
Purification notes
Purified from tissue culture supernatant. The purified antibody was conjugated under optimal conditions, with unreacted dye removed from the preparation. -
Clonality
Monoclonal -
Clone number
Avas12a1 -
Isotype
IgG2a -
Light chain type
kappa -
Research areas
Associated products
-
Recombinant Protein
Applications
Our Abpromise guarantee covers the use of ab253080 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| Flow Cyt | Use at an assay dependent concentration. Use at 0.5 μg per reaction. |
Target
-
Function
Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. -
Involvement in disease
Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma. -
Sequence similarities
Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain. -
Post-translational
modificationsPhosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 16542 Mouse
- SwissProt: P35918 Mouse
- Unigene: 285 Mouse
-
Alternative names
- CD309 antibody
- CD309 antigen antibody
- EC 2.7.10.1 antibody
see all
Images
-
Flow Cytometry - PerCP/Cy5.5® Anti-VEGF Receptor 2 antibody [Avas12a1] (ab253080)
Flow cytometric analysis of bEnd-3 (mouse brain endothelioma cell line) stained for VEGF Receptor 2 (CD309) using ab253080 at 5 μg per reaction (blue) or a rat IgG2a PerCP/Cy5.5® isotype control (dashed line).
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
References (0)
ab253080 has not yet been referenced specifically in any publications.
